Zito J M, Safer D J
University of Maryland, School of Pharmacy, Baltimore, MD 21201, USA. jzito@rx. umaryland.edu
Curr Psychiatry Rep. 2001 Apr;3(2):115-25. doi: 10.1007/s11920-001-0008-z.
This review of antidepressant treatments in children and adolescents emphasizes the gap between efficacy data derived from randomized clinical trials (RCTs) and the limited effectiveness data from community-based practices. Part one is a brief review of data from randomized, double-blind clinical trials to assess the evidence base for the major approved indications for antidepressants in youths. Part two reviews information gaps in the evidence from RCTs. Part three discusses nonexperimental evidence of the use of antidepressants, including surveys of prescription sales, physician surveys, and population-based data. Part four presents a comprehensive model for assessing the use of antidepressants in youths in the community. The model aims to answer a range of public health-oriented questions and is intended to improve treating physicians' and clinical care providers' ability to manage medications for optimal patient benefit. Suggestions are made for engaging health service providers, health insurers, academicians, advocates, and the government in building the necessary infrastructure to make effectiveness as vital as efficacy to the model of drug therapy evaluation.
这篇关于儿童和青少年抗抑郁治疗的综述强调了随机临床试验(RCT)得出的疗效数据与基于社区实践的有限有效性数据之间的差距。第一部分简要回顾了随机双盲临床试验的数据,以评估青少年抗抑郁药主要获批适应症的证据基础。第二部分回顾了随机对照试验证据中的信息差距。第三部分讨论了抗抑郁药使用的非实验性证据,包括处方销售调查、医生调查和基于人群的数据。第四部分提出了一个全面的模型,用于评估社区中青少年抗抑郁药的使用情况。该模型旨在回答一系列面向公共卫生的问题,并旨在提高治疗医生和临床护理人员管理药物以实现最佳患者受益的能力。文中还提出了一些建议,以促使健康服务提供者、健康保险公司、学者、倡导者和政府参与建设必要的基础设施,使有效性在药物治疗评估模型中与疗效同样重要。